ArticleClinical & translational immunology2022
Homologous peptides derived from influenza A, B and C viruses induce variable CD8
Article in Clinical & translational immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Deciphering influenza B virus-derived peptides and their presentation by HLA class I molecules.Biochemical Society transactions · 2026Review
- COVID-19 Vaccine Reactogenicity Marks an Innate Inflammatory Response Associated With HLA Variation and Enhanced Protection.Research square · 2026Article
- HLA micropolymorphisms confine neoantigen conformational adaptability and guide T cell receptor selectivity.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Assessing CD8Clinical & translational immunology · 2026Article
- An HLA Association With COVID-19 Vaccine Reactogenicity Correlates With Fewer SARS-CoV-2 Infections and Monocyte Activation.Research square · 2025Article
- Endothelial cell-derived apoptotic bodies modulate innate and adaptive immune responses during inflammation.Cell communication and signaling : CCS · 2025Article
- Lack of immunogenicity for an influenza-derived peptide across the HLA-B44 supertype molecules.Clinical & translational immunology · 2025Article
- Global research trends in the relationship between influenza and CD4Human vaccines & immunotherapeutics · 2024Article
- Seasonal influenza vaccines: Variability of immune responses to B lineage viruses.Human vaccines & immunotherapeutics · 2024Review
- Influenza Virus-Derived CD8 T Cell Epitopes: Implications for the Development of Universal Influenza Vaccines.Immune network · 2024Review
- CD8Nature communications · 2024Article
- Increasing HbA1c is associated with reduced CD8Cellular and molecular life sciences : CMLS · 2024Article
- Characterisation of novel influenza-derived HLA-B*18:01-restricted epitopes.Clinical & translational immunology · 2024Article
- CD8Clinical & translational immunology · 2024Article
- Fighting flu: novel CD8Clinical & translational immunology · 2024Review
- Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine.Expert review of vaccinesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Influenza A, B and C viruses (IAV, IBV and ICV, respectively) circulate globally, infecting humans and causing widespread morbidity and mortality. Here, we investigate the T cell response towards an immunodominant IAV epitope, NP Methods: We assessed the magnitude (tetramer staining) and quality of the CD8 Results: Our study provides a detailed characterisation of the CD8 Conclusion: We show that while there is a potential to cross-protect against distinct influenza virus lineages, the T cell response was stronger against the IAV peptide than IBV or ICV, which is an important consideration when choosing targets for future vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.